Hisamitsu Pharmaceutical Co., Inc. (TYO:4530)

Market Cap	442.51B +32.0%
Revenue (ttm)	159.27B +6.1%
Net Income	19.99B +28.6%
EPS	277.12 +32.7%
Shares Out	70.07M
PE Ratio	22.79
Forward PE	25.87
Dividend	45.00 (0.69%)
Ex-Dividend Date	Aug 28, 2025

Volume	634,700
Average Volume	389,285
Open	6,300.00
Previous Close	6,315.00
Day's Range	6,190.00 - 6,328.00
52-Week Range	3,783.00 - 6,695.00
Beta	0.35
RSI	58.57
Earnings Date	Apr 9, 2026

About TYO:4530

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete′s foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to Asi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1847
• Employees: 2,799
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4530

Financial Performance

In fiscal year 2025, TYO:4530's revenue was 156.01 billion, an increase of 10.09% compared to the previous year's 141.71 billion. Earnings were 21.76 billion, an increase of 55.76%.